ArticleGut1994
Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.
Article in Gut, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 73 citations in OpenAlex.
- A-to-I RNA co-editing predicts clinical outcomes and is associated with immune cells infiltration in hepatocellular carcinoma.Communications biology · 2024Article
- Prognostic role ofOncology letters · 2016Article
- Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Review
- ß-Catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.International journal of colorectal disease · 2013Article
- Prognostic and predictive roles of KRAS mutation in colorectal cancer.International journal of molecular sciences · 2012Review
- A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.The oncologist · 2010Review
- Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Journal of the National Cancer Institute · 2009Review
- Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.International journal of colorectal disease · 2004Review
- High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas.Oncogene · 2002Article
- What we could do now: molecular pathology of colorectal cancer.Molecular pathology : MP · 2001Review
- Article
- Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.British journal of cancer · 1998Article
- The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system.British journal of cancer · 1998Article
- Genetic prognostic markers in colorectal cancer.Molecular pathology : MP · 1997Review
- Article
- Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The series of genetic changes leading to malignancy in colorectal cancer is well reported. This includes mutational activation of the proto-oncogene Ki-ras and mutation/deletion of the p53 tumour suppressor gene. The frequency of these mutations was investigated in a panel of 52 colorectal cancer patients using a combination of immunocytochemistry and non-radioactive, digoxigenin-labelled in situ hybridisation. Sixty two per cent (32 of 52) of the study population were positive for p53 overexpression and 36% (19 of 52) positive for Ki-ras mutation. Twenty seven per cent (14 of 52) of the patients expressed both mutations. Mutation of either the p53 or the Ki-ras gene did not correlate with Dukes's stage, tumour differentiation or 5 year survival rate of the patients. Most of the rectal carcinoma specimens (11 of 15) showed p53 over-expression but the significance of this was not supported statistically. Thus detection of molecular changes is becoming more amenable to incorporation into routine histological carcinoma assessment because of the advent of non-radioactive labelling in in situ hybridisation and antibodies suitable for paraffin wax embedded specimens. The significance of these mutations in disease prognosis, however, remains questionable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.